Caris

The Irving, Texas-based company claims that three of Foundation Medicine's cancer molecular profiling tests infringe five of its US patents.

The study will perform next-generation sequencing on archival tumor tissue from 200 individuals with metastatic urothelial cancer.

The companies will perform tumor profiling to identify patients with genetic abnormalities that could make them eligible for treatment in the NCI study.

There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.

Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.

Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression. 

There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.

The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.

Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.

COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.

Pages

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.